Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Sanofi-aventis and JDRF partner for type 1 diabetes therapeutics

July 5, 2010

GPR119 agonist AS-1535907 regulates insulin expression and pancreatic beta-cell mass in vivo

July 5, 2010

Euroscreen claims new GPR43 agonists/partial agonists

July 5, 2010

Eisai to market lorcaserin for obesity and weight management in the U.S.

July 2, 2010

Endo submits complete response to FDA regarding NDA for Fortesta

July 2, 2010

FDA accepts for review BioMimetic's PMA for Augment bone graft

July 2, 2010

New glucagon receptor antagonist DSR-17759 shows antidiabetic promise in preclinical evaluation

July 2, 2010

DPP-IV inhibitor LC15-0444 safe and improves glycemic control in Korean type 2 diabetes patients

July 2, 2010

Alnylam obtains approval to initiate phase I ALN-TTR01 study in amyloidosis

July 1, 2010

Tolerx begins confirmatory phase III trial of otelixizumab in type 1 diabetes

July 1, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...